

| | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|----------------|-------------|------------------|-------------|-----------------|-------------|------------------|-------------|---------------------|-------------|------------------|-------------|-----------------|-------------|------------------|-------------|-----------------|-------------|------------------|-------------|------------------|-------------|-------------------|-------------|
| NRTI Mutations: | None | | | | | | | | | | | | | | | | | | | | | | | | |
| NNRTI Mutations: | None | | | | | | | | | | | | | | | | | | | | | | | | |
| RT Other Mutations: | S519N <small>100% HIV-1_H11T</small> • Q524K <small>99% HIV-1_H1T2</small> • K527E <small>99% HIV-1_H12_189</small> • E529D <small>99% HIV-1_H12_189</small> • A534S <small>99% HIV-1_H12_189</small> • A554S <small>99% HIV-1_H12_189</small> | | | | | | | | | | | | | | | | | | | | | | | | |
| <div><div><div>Nucleoside Reverse Transcriptase Inhibitors</div><table><tr><td>abacavir (ABC)</td><td>Susceptible</td></tr><tr><td>zidovudine (AZT)</td><td>Susceptible</td></tr><tr><td>stavudine (D4T)</td><td>Susceptible</td></tr><tr><td>didanosine (DDI)</td><td>Susceptible</td></tr><tr><td>emtricitabine (FTC)</td><td>Susceptible</td></tr><tr><td>lamivudine (3TC)</td><td>Susceptible</td></tr><tr><td>tenofovir (TDF)</td><td>Susceptible</td></tr></table></div><div><div>Non-nucleoside Reverse Transcriptase Inhibitors</div><table><tr><td>doravirine (DOR)</td><td>Susceptible</td></tr><tr><td>efavirenz (EFV)</td><td>Susceptible</td></tr><tr><td>etravirine (ETR)</td><td>Susceptible</td></tr><tr><td>nevirapine (NVP)</td><td>Susceptible</td></tr><tr><td>rilpivirine (RPV)</td><td>Susceptible</td></tr></table></div></div> | | abacavir (ABC) | Susceptible | zidovudine (AZT) | Susceptible | stavudine (D4T) | Susceptible | didanosine (DDI) | Susceptible | emtricitabine (FTC) | Susceptible | lamivudine (3TC) | Susceptible | tenofovir (TDF) | Susceptible | doravirine (DOR) | Susceptible | efavirenz (EFV) | Susceptible | etravirine (ETR) | Susceptible | nevirapine (NVP) | Susceptible | rilpivirine (RPV) | Susceptible |
| abacavir (ABC) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| zidovudine (AZT) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| stavudine (D4T) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| didanosine (DDI) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| emtricitabine (FTC) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| lamivudine (3TC) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| tenofovir (TDF) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| doravirine (DOR) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| efavirenz (EFV) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| etravirine (ETR) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| nevirapine (NVP) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |
| rilpivirine (RPV) | Susceptible | | | | | | | | | | | | | | | | | | | | | | | | |

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

| | | | | | | | | | | | |
|--|--|-------------------|-------------|--------------------|-------------|--------------------|-------------|--------------------|-------------|-------------------|-------------|
| INSTI Major Mutations: | None | | | | | | | | | | |
| INSTI Accessory Mutations: | None | | | | | | | | | | |
| IN Other Mutations: | K14R <small>99% HIV-1_H12_190</small> • S175N <small>1% HIV-1_H12_190</small> • S24N <small>99% HIV-1_H12_190</small> • K34R <small>100% HIV-1_H12_190</small> • M50I <small>100% HIV-1_H12_190</small> • I72V <small>100% HIV-1_H12_190</small> • T112V <small>100% HIV-1_H12_190</small> • I113V <small>100% HIV-1_H12_190</small> • T124TA <small>1% HIV-1_H12_190</small> • T125A <small>100% HIV-1_H12_190</small> • K136Q <small>99% HIV-1_H12_190</small> • D167E <small>99% HIV-1_H12_190</small> • V201I <small>99% HIV-1_H12_190</small> • I208M <small>100% HIV-1_H12_190</small> • N222K <small>100% HIV-1_H12_190</small> • L234V <small>100% HIV-1_H12_190</small> • S283G <small>100% HIV-1_H12_190</small> | | | | | | | | | | |
| <div><div><div>Integrase Strand Transfer Inhibitors</div><table><tr><td>bictegravir (BIC)</td><td>Susceptible</td></tr><tr><td>cabotegravir (CAB)</td><td>Susceptible</td></tr><tr><td>dolutegravir (DTG)</td><td>Susceptible</td></tr><tr><td>elvitegravir (EVG)</td><td>Susceptible</td></tr><tr><td>raltegravir (RAL)</td><td>Susceptible</td></tr></table></div></div> | | bictegravir (BIC) | Susceptible | cabotegravir (CAB) | Susceptible | dolutegravir (DTG) | Susceptible | elvitegravir (EVG) | Susceptible | raltegravir (RAL) | Susceptible |
| bictegravir (BIC) | Susceptible | | | | | | | | | | |
| cabotegravir (CAB) | Susceptible | | | | | | | | | | |
| dolutegravir (DTG) | Susceptible | | | | | | | | | | |
| elvitegravir (EVG) | Susceptible | | | | | | | | | | |
| raltegravir (RAL) | Susceptible | | | | | | | | | | |

IN comments

Other

- M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-naïve persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It may contribute to reduced DTG and CAB susceptibility in combination with R263K.

No drug resistance mutations were found for INSTI.